

WHO Expert Committee on Drug Dependence

Forty-fourth report



World Health
Organization

The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO's constitutional functions is to provide objective, reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications.

The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of-the-art consensus reports that offer technical advice and recommendations for decision-makers. These books are closely tied to the Organization's priority activities, encompassing disease prevention and control, the development of equitable health systems based on primary health care, and health promotion for individuals and communities. Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of all WHO's Member countries and the collaboration of world leaders in public health and the biomedical sciences. To ensure the widest possible availability of authoritative information and guidance on health matters, WHO secures the broad international distribution of its publications and encourages their translation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO's books contribute to achieving the Organization's principal objective – the attainment by all people of the highest possible level of health.

The WHO Technical Report Series makes available the findings of various international groups of experts that provide WHO with the latest scientific and technical advice on a broad range of medical and public health subjects. Members of such expert groups serve without remuneration in their personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated policy of WHO. To purchase WHO publications, please contact: WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland; email: bookorders@who.int; order on line: <http://apps.who.int/bookorders>).

W H O T e c h n i c a l R e p o r t S e r i e s
1 0 3 8

WHO Expert Committee on Drug Dependence

Forty-fourth report

This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization



**World Health
Organization**

WHO Expert Committee on Drug Dependence: forty-fourth report

(WHO Technical Report Series, No. 1038)

ISBN 978-92-4-004283-4 (electronic version)

ISBN 978-92-4-004284-1 (print version)

ISSN 0512-3054

© World Health Organization 2022

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. WHO Expert Committee on Drug Dependence: forty-fourth report. Geneva: World Health Organization; 2022 (WHO Technical Report Series, No. 1038). Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <https://www.who.int/copyright>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the policies of WHO.

Layout L'IV Com Saràl

Contents

Acknowledgements	iv
Abbreviations and acronyms	vi
Executive summary	viii
1. Information session	x
2. Meeting report of the 44th Expert Committee on Drug Dependence	1
2.1 Updates on ECDD meeting recommendations and outcomes	2
2.1.1 Recommendations by the 41st ECDD on cannabis and cannabis-related substances	2
2.1.2 Recommendations by the 43rd ECDD	3
2.1.3 Recommendations by the 9th ECDD Working Group	3
2.2 Recommendations for international control of psychoactive substances	4
2.2.1 4F-MDMB-BICA (4F-MDMB-BUTICA)	4
2.2.2 Brorphine	6
2.2.3 Metonitazene	7
2.2.4 Eutylone (3,4-methylenedioxy- α -ethylamino butiophenone)	9
2.2.5 Benzylone (3,4-methylenedioxy- <i>N</i> -benzylcathinone)	10
2.3 Recommendations on preliminary reviews (pre-reviews)	11
2.3.1 Kratom, mitragynine, 7-hydroxymitragynine	11
2.3.2 Phenibut (4-amino-3-phenyl-butyric acid)	13
3. Critical review and pre-review reports	16
3.1 Critical review reports	16
3.1.1 4F-MDMB-BICA	16
3.1.2 Brorphine	24
3.1.3 Metonitazene	40
3.1.3 Eutylone	58
3.1.4 Benzylone	68
3.2 Pre-review reports	80
3.2.1 Kratom (<i>Mitragyna speciosa</i>), mitragynine and 7-hydroxymitragynine	80
3.2.2 Phenibut	110
References	128
Annex 1. Report on the WHO Member State questionnaire for review of psychoactive substances	153
Annex 2. List of participants	186

Acknowledgements

The World Health Organization (WHO) is grateful for the contributions of many individuals and organizations to this Expert Committee. The 44th meeting of the Expert Committee on Drug Dependence (ECDD) was organized under the overall direction of Mariângela Simão (WHO Division of Access to Medicines and Health Products, Geneva, Switzerland) and Gilles Forte (Geneva, Switzerland). Dilkushi Poovendran (Geneva, Switzerland) coordinated the work of the meeting with the support of Suzanne Nielsen and Tina Lam (Monash University, Melbourne, Australia) and Judith Sprunken and Patricia Gevrey (WHO, Geneva, Switzerland).

The secretariat gratefully acknowledges the technical guidance and inputs provided by all members of the following groups of contributors:

Authors of critical and pre-review reports:

4F-MDMB-BICA: Giuseppe Cannazza^{1*}, Cinzia Citti^{2*}, Jenny Wiley

Benzyllone: Simon Brandt³

Brorphine: Simon Brandt³

Eutylone: Giuseppe Cannazza^{1*}, Cinzia Citti^{2*}, João Silva⁴

Kratom, mitragynine, 7-hydroxymitragynine: Giuseppe Cannazza^{1*}, Cinzia Citti^{2*}, David Gorelick⁵

Metonitazene: Giuseppe Cannazza^{1*}, Cinzia Citti^{2*}, Jermaine Jones⁶

Phenibut: Giuseppe Cannazza^{1*}, Cinzia Citti^{2*}, Teresa Franklin⁷

¹ University of Modena and Reggio Emilia, Italy

² Institute of Nanotechnology of the National Council of Research, Italy

³ Liverpool John Moores University, UK

⁴ University of Porto, Portugal

⁵ University of Maryland, USA

⁶ New York State Psychiatric Institute / Columbia University Medical Center, USA

⁷ University of Pennsylvania, USA

*The indicated authors led the development of the chemistry sections

44th ECDD Committee Members: Patrick Beardsley, Wim Best, Sandra Comer, Ifeoma Ekwere, Simon Elliott, Raka Jain, Pamela Kaduri (Rapporteur), Junichi Kitanaka, Antonio Pascale Prieto, Afarin Rahimi-Movaghar (Co-Chair), Sutisa Thanoi and Jason White (Chair).

The WHO secretariat thanks the European Monitoring Centre for Drugs and Drug Addiction for providing data on benzylone collected in the European Union Early Warning System, which includes data provided by Reitox national focal points in the European Union Member States, Turkey and the Europol National Units.

The WHO Secretariat also thanks Dr Alex J. Krotulski (Center for Forensic Science Research and Education, Fredric Rieders Family Foundation, Willow Grove (PA), USA) and Dr Michael H. Baumann (Designer Drug Research Unit, National Institute on Drug Abuse, Baltimore (MD), USA) for providing information and support.

The Secretariat gratefully acknowledges the participation of the United Nations Office on Drugs and Crime (UNODC) and the International Narcotics Control Board (INCB) in the meeting and for providing data. Technical data were also received from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) and from Member States who contributed to prioritizing substances and provided information to the Secretariat through the Member State questionnaire.



Abbreviations and acronyms

4-ANPP	4-anilino- <i>N</i> -phenethyl piperidine
CB ₁	cannabinoid
CFSRE	Center for Forensic Science Research and Education (USA)
CND	Commission on Narcotic Drugs
CYP	cytochrome P450
DAMGO	[D-Ala ² , <i>N</i> -mePhe ⁴ , Gly-ol]-enkephalin
DART	direct analysis in real time
DAT	dopamine receptor transporter
DEA	Drug Enforcement Administration (USA)
DMF	dimethylformamide
DMSO	dimethylsulfoxide
DUID	driving under the influence of drugs
EC ₅₀	half maximal effective concentration
ECDD	Expert Committee on Drug Dependence
ED ₅₀	median effective dose
EMCDDA	European Monitoring Centre for Drugs and Drug

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_23303

